{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    8,
    39,
    40
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.8,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_6",
        "affectedSection": "Global - Protocol Versioning",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Incorporation of Nonsubstantial Amendment 6 into Version 5.1"
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_6",
        "affectedSection": "Section 2.2.1 - Study Design",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated survival follow-up and Quality of Life (QoL) data collection requirements following the final Overall Survival (OS) analysis."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_6",
        "affectedSection": "Section 12.7 - Clinical Study Continuity",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added provisions for clinical study continuity and transition to other Astellas-sponsored studies."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_6",
        "reasonText": "To define the completion of survival follow-up and QoL assessments once the target number of OS events is reached.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_6",
        "reasonText": "To provide a mechanism for subjects still receiving clinical benefit to transition to open-label treatment in separate studies after study termination.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "beforeText": "null",
        "afterText": "Once the final number of events has been reached to trigger the final OS analysis, survival follow-up will be considered complete and subjects will be discontinued from long term follow-up.",
        "summary": "Clarified the end of survival follow-up period."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "beforeText": "The following assessments of prostate cancer status will be collected during the course of the study: PSA, soft tissue disease on CT scan or on MRI, bone disease on radionuclide bone scans, survival status, EQ-5D-5L, QLQ-PR25, FACT-P for QoL and BPI-SF for pain symptom assessment.",
        "afterText": "The following assessments of prostate cancer status will be collected during the course of the study: PSA, soft tissue disease on CT scan or on MRI, bone disease on radionuclide bone scans, survival status, EQ-5D-5L, QLQ-PR25, FACT-P for QoL and BPI-SF for pain symptom assessment. Once the final number of events has been reached to trigger the final OS analysis, sites will no longer be required to collect EQ-5D-5L, QLQ-PR25, FACT-P for QoL and BPI-SF.",
        "summary": "Discontinued QoL assessment collection after final OS analysis trigger."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_6",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "2.2.1",
        "beforeText": "null",
        "afterText": "Subjects who are continuing to receive clinical benefit from treatment with enzalutamide after the OS analysis data cutoff or at study termination and have not met any discontinuation criteria may continue their open-label treatment in another Astellas-sponsored study.",
        "summary": "Added provision for transition to open-label extension studies."
      }
    ],
    "summary": {
      "impactCount": 3,
      "reasonCount": 2,
      "changeCount": 3
    }
  }
}